NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy

Abstract Checkpoint blockade-mediated immunotherapy is emerging as an effective treatment modality for multiple cancer types. However, cancer cells frequently evade the immune system, compromising the effectiveness of immunotherapy. It is crucial to develop screening methods to identify the patients...

Full description

Bibliographic Details
Main Authors:	Sayuri Yoshihama, Steven X. Cho, Jason Yeung, Xuedong Pan, Gregory Lizee, Kranti Konganti, Valen E. Johnson, Koichi S. Kobayashi
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-82729-9

Similar Items

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01)

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
by: Brian J. Ahn, et al.
Published: (2013-11-01)

Epigenetic checkpoint blockade: new booster for immunotherapy
by: Ziqiao Wang, et al.
Published: (2021-07-01)

New development of Immune checkpoints blockade in cancer immunotherapy
by: Wu Feixuan
Published: (2019-01-01)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
by: Shu-Jen Chen, et al.
Published: (2020-06-01)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
by: Ju Yeon Lee, et al.
Published: (2016-10-01)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
by: Xiaolei Li, et al.
Published: (2018-02-01)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
by: Robert W. Wilkinson, et al.
Published: (2018-06-01)

Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma
by: Tietze Stefanie, et al.
Published: (2021-04-01)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
by: Xiaopin Duan, et al.
Published: (2019-04-01)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
by: Yun Hua Lee, et al.
Published: (2020-09-01)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
by: Kripa Guram, et al.
Published: (2019-03-01)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
by: Jingjing Duan, et al.
Published: (2018-09-01)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
by: Lin X, et al.
Published: (2021-03-01)

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy
by: Kaiyuan Ni, et al.
Published: (2018-06-01)

The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy
by: Huan Zhao, et al.
Published: (2018-01-01)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
by: Shangqin Sun, et al.
Published: (2021-04-01)

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
by: Masaki Terabe, et al.
Published: (2017-05-01)

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
by: Tianhang Li, et al.
Published: (2021-08-01)

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
by: Marine Leclerc, et al.
Published: (2019-07-01)

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
by: Qian Chen, et al.
Published: (2016-10-01)

Combining photothermal ablation-based vaccine with immune checkpoint blockade for synergistic osteosarcoma immunotherapy
by: Xingyu Zhao, et al.
Published: (2021-01-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
by: Ilenia Aversa, et al.
Published: (2020-03-01)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
by: Shashi Gujar, et al.
Published: (2018-08-01)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
by: Meihua Wang, et al.
Published: (2019-02-01)

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
by: Robert D. Leone, et al.
Published: (2015-01-01)

Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
by: Eiko Hayase, et al.
Published: (2021-06-01)

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response
by: Kripa Guram, et al.
Published: (2018-10-01)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
by: Janna Krueger, et al.
Published: (2021-01-01)

Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
by: Yu-Chen Chuang, et al.
Published: (2020-05-01)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
by: Sama Rezasoltani, et al.
Published: (2021-02-01)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
by: Laura Boyero, et al.
Published: (2020-12-01)

Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
by: Isabella McGoverne, et al.
Published: (2020-04-01)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
by: Fei Tang, et al.
Published: (2018-04-01)

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
by: Giorgio Parmiani, et al.
Published: (2015-05-01)

Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature
by: Paul Riviere, et al.
Published: (2021-04-01)

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
by: Regev, Aviv
Published: (2020)

The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
by: Akhil Shukla, et al.
Published: (2021-02-01)